Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Acrivon Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, August 11, 2023 - Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the second quarter ended June 30, 2023 and provided business highlights. “The Acrivon team has made significant progress during the second quarter, both on the clinical and preclinical development fronts, as well as with the expansion of our board and executive leadership team with strategic additions,” said Peter Blume-Jensen, ..." |
|
| 05/09/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
8-K
| Quarterly results |
|
|